3P Biopharmaceuticals and the Oxford University spin-out, SpyBiotech, have signed a contract for vaccine production. Contract management is a determining factor in the provision of shared services and services that are more difficult to control or fully register in the contractual language often remain under local control. In the 2007 survey of U.S. city officials, the most difficult service was judged to be the operation and management of hospitals and the cleaning of the least difficult streets and parking lots. The study found that municipalities often do not adequately monitor collaborative agreements or other forms of service delivery: “For example, in 2002, only 47.3% of executives who work with private companies as suppliers reported evaluating these services. In 2007, this figure was still 45.4%. Performance monitoring is a general concern of these surveys and of the scientific criticisms leveled against these rules.   A 2013 study published in the State and Local Government Review found that definitions of public-private partnerships vary considerably from municipality to municipality: “Many public and private public servants insult public-private partnerships for any number of activities, where the relationship is actually contractual, franchised or the burden that utilities previously generate to a private or not-for-profit organization. A broader term for these agreements is “common service delivery,” in which public bodies work with private companies or non-profit organizations to provide services to citizens.   “We are very pleased to be working with Affibody on this project and to create a strong long-term partnership with them. We are confident that this is a mutually beneficial agreement,” said D`maso Molero, Managing Director of 3P Biopharmaceuticals. In June 2019, SpyBiotech 3P selected biopharmaceuticals for the production of a good manufacturing practice (CGMP) of its virus-type particle carrier, with the aim of completing production in 2021. With this recent agreement, 3P Biopharmaceuticals will demonstrate its ability to perform processes and produce molecules designed for various therapeutic applications. In April 2010, the Alberta government reached an agreement with B2L Partnership for the DBFM of 10 new Alberta schools.
Construction of the school was completed in June 2012. In September 2008, the Alberta government reached an agreement with BBPP Alberta Schools Limited for the design, construction, financing and maintenance (DBFM) of 18 new schools. Construction of the school was completed in June 2010. The Contract Development and Manufacturing Organization (CDMO), 3P Biopharmaceuticals and the Oxford University spin-out SpyBiotech have signed a vaccine production contract, as announced in October.